Creabilis Appoints Dr. Eliot Forster as its New Chief Executive Officer

LUXEMBOURG, September 29, 2010 - Creabilis SA, a clinical stage European biotechnology company
addressing significant unmet medical needs in dermatological diseases, today
announced the appointment of Eliot Forster as its new Chief Executive
Officer. Dr Forster brings to Creabilis significant drug development
experience having brought a number of molecules to market.

Dr Forster has close to 20 years industry experience in
biotechnology and pharmaceutical companies. He was most recently the CEO of
Solace Pharmaceuticals, a US-based biotech. Prior joining Solace, Dr Forster
was Head of EU Development and of Development Operations in the EU & Asia at
Pfizer. During his career at Pfizer Dr Forster was integral to bringing a
number of drugs to market, including Celebrex(R) (celecoxib), Bextra(R)
(valcecoxib) and Relpax(R) (eletriptan).

Dr Forster holds a PhD from Liverpool University and an M.B.A.
from Henley Management College. He has held a number of Non-Executive
Director roles in the biotech sector and is an advisor to the UKTI Life
Sciences Strategy Board.

Commenting on his new role, Dr Eliot Forster said: "Creabilis
has the potential to make a significant difference to the way serious skin
diseases are treated. Our lead product, CT327, is advancing through the
clinic and highlights the potential of our Low Systemic Exposure (LSE)
technology to deliver innovative new chemical entities, targeting significant
unmet medical needs. I very much look forward to working with the exceptional
team at Creabilis and delivering on the undoubted promise of the Company's
pipeline and underlying science."

George F. Horner III, Chairman of Creabilis, said: "We are
delighted that Eliot has joined Creabilis. His proven drug development
experience will be extremely valuable as we work to further advance of our
exciting pipeline of clinical drug candidates. Eliot's appointment is another
important step in Creabilis bringing highly innovative treatments for skin
diseases to market."

About Creabilis SA

Creabilis is a clinical stage European biotechnology company
creating highly innovative new drugs to tackle unmet medical needs in serious
dermatological diseases. Bringing together world class drug development
capabilities and a rich scientific heritage, Creabilis is uniquely positioned
to transform the treatment of skin diseases.

Creabilis' lead product is CT327, a novel topically applied
TrkA kinase inhibitor developed using the Company's LSE (Low Systemic
Exposure) technology. LSE technology creates new chemical entities with ideal
characteristics for topical application (high local concentrations combined
with low systemic exposure). CT327 is currently in Phase II clinical trials
in psoriasis and atopic dermatitis. The Creabilis portfolio also includes
CT637, a new approach to the treatment of significant inflammatory conditions
such as rheumatoid arthritis as well as severe psoriasis. Earlier stage
projects include a number of highly promising candidates for dermatological
and wider indications.

Creabilis is backed by some of Europe's most highly respected
life sciences investors including Sofinnova Partners and Neomed.

For more information, please visit: www.creabilis-sa.com

    For further information please contact:
    Creabilis
    Eliot Forster
    eforster@creabilis-sa.com
    Creabilis SA
    15 Rue Edward Steichen
    L-2540 LUXEMBOURG
    Citigate Dewe Rogerson
    Chris Gardner or Nina Enegren
    Tel: +44(0)20-7282-1050
    E-mail: nina.enegren@citigatedr.co.uk

For further information please contact: Creabilis, Eliot Forster, eforster at creabilis-sa.com, Creabilis SA, 15 Rue Edward Steichen, L-2540 LUXEMBOURG, Citigate Dewe Rogerson, Chris Gardner or Nina Enegren, Tel: +44(0)20-7282-1050, E-mail: nina.enegren at citigatedr.co.uk